Back to search

Aristotle University Of Thessaloniki (AUTH)

Γονοτύπηση με αλληλούχιση νέας γενιάς ασθενών με οικογενή μεσογειακό πυρετό και μακροχρόνια παρακολούθηση της πορείας της νόσου με σύγχρονες μεθόδους

Abstract

dc:description

Familial Mediterranean Fever (FMF) is the most common monogenic autoinflammatory disease, which is traditionally inherited with the autosomal recessive pattern. It is common in people of Mediterranean descent, especially Jews, Armenians, Turks and Arabs, and less commonly in Spanish, Italians, Greeks and Portuguese.A typical attack is characterized by fever and serositis (peritonitis, pleuritis, arthritis) and usually lasts 12-72 hours. During attack free periods, patients are asymptomatic and seemingly healthy. The duration and frequency of attacks vary widely both in patients and between different groups of patients. In addition, data suggest that subclinical inflammation may occur during attack free periods. A complication of uncontrolled disease activity is the development of amyloidosis, which is attributed to insufficient or no treatment. Over time, serum amyloid A is deposited in tissues and organs throughout the body. It usually affects the kidneys, leading to proteinuria and end-stage chronic kidney disease.FMF is caused by mutations in the MEFV (MEditerraneanFeVer) gene, which is located on the short arm of chromosome 16, at position 16p13.3 and contains 10 exons. The gene encodes the protein pyrin that is involved in regulating inflammation. More specifically, pyrin is a component of the inflammasome, a protein complex that regulates the production of an inflammatory cytokine, IL-1β, which is responsible for FMF attacks. More than 365 MEFV mutations have been officially recorded to date in the international INFEVERS database, located mainly in exons 10 and 2. The 5 most common mutations in Mediterranean people are M694V, V726A, M680I, M694I and E148Q corresponding to 65-95% of all patients. Molecular analysis can detect one or more mutations (heterozygosity, homozygosity, compound heterozygosity or complex genotype), while in a percentage of patients no mutation is isolated. Conventional methods, such as PCR, are applied for genotyping patients, but also newer techniques, such as Next Generation Sequencing (NGS).The diagnosis of FMF remains clinical, supported by genotyping, but not excluded when no mutations are detected.The treatment is the lifelong intake of colchicine. Colchicine suppresses the onset of recurrent attacks in the vast majority of patients and at the same time prevents the development of amyloidosis. In colchicine-resistant cases, the administration of biological anti-IL-1β agents is applied. With scheduled periodic follow-up of patients and adherence to treatment, the outcome of FMF and the quality of life of patients is very satisfactory.Until the design of this thesis, there were no studies and data in the Greek literature in large series of patients regarding the recording of clinical, laboratory and genetic profile in Greek patients with FMF. Therefore, the primary objectives of this doctoral dissertation were: a) To record the clinical and laboratory profile of these patients, their genotype, course and outcome with contemporary tools, as well as its ultimate complications for a long time up to 30 years b) Also to look for new mutations in single heterozygotes and in patients with normal genotype, but clinical phenotype compatible with FMF with the application of more extensive genotyping with NGS. Secondary objectives of this thesis were: a) The evaluation of the severity, course and outcome of the disease b) The detection of clinical-laboratory correlations, in order to find prognostic factors for the outcome of the disease and the subsequent therapeutic interventions c) The phenotype-genotype correlation to assess the importance and severity of the mutations d) Detection of early subclinical inflammation e) Evaluation of response to treatment for early identification of colchicine-resistant patients, candidates for biologic therapies f) The evaluation of patients' compliance to treatment, as well as to their clinical monitoring g) The detection of complications of the disease, in order to carry out timely therapeutic intervention h) The recording and evaluation of the central blood pressure and the parameters of arterial stiffness (PWV and AIx75) i) The assessment of quality of life of patients with FMF.The population included in this thesis consisted of 94 patients with FMF, who are monitored at the Pediatric Immunology and Rheumatology Reference Center (PARKA) of the 1st Department of Pediatrics of Aristotle University of Thessaloniki, 5 of which had made their transition to Adult Clinic with Rheumatic and Autoinflammatory Disease of the 4th Department of Internal Medicine of Aristotle University of Thessaloniki. Patients fulfilling the inclusion/exclusion criteria of the study, who gave their written consent after a detailed briefing on the procedures of the research protocol, were invited to participate in the study. Long-term follow-up by our center allowed the recording of the clinical phenotype at the disease onset, the genetic profile, as well as the monitoring of the course and outcome of the disease, the response to treatment, patient compliance and the recording of long-term complications. For their evidence-based follow-up, contemporary tools were applied, which enabled the valid and more detailed evaluation of these patients.From the patients, 31 whose genetic analysis did not reveal a confirmatory genotype for the disease, presenting with heterozygosity or normal genotype, underwent further molecular analysis with NGS, in order to investigate the existence of additional mutations.At the same time, in 43 of the 94 patients, as well as in 42 healthy controls, Systolic Blood Pressure was measured, and a study of arterial stiffness parameters, Pulse Wave Velocity (PWV) and Augmentation Index (AIx75) was performed, using the SphygmoCor XCEL device, in order to assess early changes in the artery wall, due to the chronic inflammation observed in this group of patients.The study showed a number of important results. The study of the clinical phenotype showed that the majority of patients developed the disease during infancy (mean age 3.49 years). The clinical phenotype at the onset of the disease in patients who were mainly pediatric, included fever, abdominal pain, arthralgia and thoracic pain at high rates of 96.8%, 85.1%, 54.3% and 45.7% respectively. At lower rates patients presented with arthritis (21.3%), myalgia (20.2%), diarrhoea (19.1%), vomiting (19.1%), erysipelas-like rash (10.6%), lymphadenopathy (8.5%), splenomegaly (6.4%) and orchitis (2.1%). Arthritis more commonly affected the knees and ankles in 70% and 75% of patients respectively and arthralgia also the knees and ankles in 58.8% and 43.13% of patients respectively. The duration of attacks for 87.2% of patients was 1-3 days. The severity of the disease was assessed at baseline with the contemporary tool ISSF and it was found that 36.2% had mild disease, 62.7% moderate disease and only one patient had severe disease. The severity of the disease was correlated with various parameters and a statistically significant correlation was found with the M694V mutation and with M694V/M694V homozygosity (p=0.00 and p=0.001 respectively). It was also significantly correlated with clinical phenotype and specifically with rheumatic manifestations [arthritis (p=0.00)/arthralgia (p=0.002)], chest pain (p=0.00), erysipelas-like rash (p=0.001) and myalgia (p =0.00).No renal amyloidosis was observed in patients.All patients were treated with colchicine. The response to treatment was assessed using the contemporary tool FMF50 and a statistically significant correlation was found with compliance to treatment (p=0.00). At 6 months from the treatment onset an improvement>50% was recorded in 67.02% of patients. However, due to the increased percentage of non-compliance to treatment, the experiential education of the patients was improved and the dose of colchicine was adjusted, where needed. The FMF50 was re-applied at12 months after treatment onset, having the biological agent Canakinumab added to the treatment of three patients, as also at the end of the patients΄ follow-up, in the context of the thesis, and 95.7% and 98.9% improvement rates were observed, respectively. The above correlation clearly proves the essential contribution of patients' compliance to the suppression of the disease activity and its good outcome.The application of the conventional genotyping techniques PCR and NIRCA captured the genetic profile of patients, which consisted of the following more frequent mutations: M694V (55.3%), M680I (29.8%), V726A (8.5%) and E148Q (7.4%). The mutations M694I (3.2%), R761H, K695R and P369S were detected at lower frequencies (2.1% each). Molecular testing with NIRCA identified additional mutations, which PCR does not include in its own panel. These were R202Q (9.6%), E230K (2.1%), A761H and M694Q (1.1% each). Based on the number of mutations, it was observed that homozygotes constituted 22.3% of the patients, heterozygotes 34%, compound heterozygotes 30.9%, while patients with complex genotype 3.2%. Absence of mutation was observed in 9.6% of patients.The majority of patients showed a good quality of life, as evidenced by the evaluation of the GHQ-28 and SMILY-Illness questionnaires that the patients completed. According to the GHQ-28 questionnaire, only 3 of the 78 patients were found to have some degree of psychological disorder, while the mean value of the SMILY-Illness questionnaire, which was extremely high 81.17 ± 11.93, proves the small effect of the disease on patients' quality of life. In 31 patients with a clinical diagnosis of FMF without genetic confirmation by PCR or NIRCA, molecular testing with NGS was performed. This method genetically confirmed the clinical diagnosis in 19 patients (61.3% of patients). Among them, two patients who had a normal genotype according to conventional methods, were shown to have a complex genotype, confirming their severe clinical phenotype. In the remaining 17 patients, all with heterozygous genotype, NGS identified 7 patients with a complex genotype, 8 with compound heterozygosity and 1 with homozygosity, findings that support diagnosis and treatment decisions. In the present study, the application of NGS altered the distribution of mutations. According to the conventional methods, the most common mutations were M694V, M680I and R202Q with percentages of 29%, 16.1% and 12.9% respectively, while after the application of NGS the frequencies changed as follows: R202Q (61.3%), M694V (48.4%) and M680I (19.4%). Overall, the R202Q mutation was detected in 73% of patients and more specifically in 40% of heterozygotes, 77.7% of compound heterozygotes and 90.9% of patients with a complex genotype. Mutation R202Q was associated with the clinical FMF phenotype. At the same time, rare mutations (R761H, E148V, E167D, F479L, R408Q and P369S) were detected, that PCR could not identify. Central blood pressure and arterial stiffness parameters were recorded in 43 of the 94 patients in the study, as well as in 42 healthy controls. Patients were divided into subgroups, according to the response to treatment (complete or partial) and the frequency of attacks, depending on whether it was greater or less than 2 months. Patients with FMF showed higher values of AIx75 compared to controls (19.76% versus 9.96%, p<0.05), showing a statistically significant difference. In contrast, no statistically significant difference was observed in Systolic Blood Pressure (SBP), Diastolic Blood Pressure (DBP), Central Systolic Blood Pressure (cSBP) and cf-PWV. The response to colchicine was an important prognostic factor for AIx75, proving that chronic inflammation can affect arterial stiffness. The mean value of cf-PWV in the patient group was 4.97 ± 1.05 m/sec (IQR 4.31-5.48) and in control group 5.04 ± 1.08 m/sec (IQR 4.2-5.96). AIx75 was associated with pathogenic mutations and was found to have a statistically significant association with the genotype M694V/M680I (33.71±17.81% vs. 16.6±20.53%, p<0.05), but not with the genotypes M694V/0, M694V/M694V, M680I, M680I/M680I and other less common. AIx75 was also higher in the subgroup of patients with partial response to treatment, showing a statistically significant difference. This difference persisted even after adjustment for age and gender (estimated mean values 14.25%, 95% CI 6.09 to 21.96 for full response versus 31.81%, 95% CI 21.40 to 42.58 for partial response, p<0.05). The cf-PWV showed a positive correlation with age (B=0.09, 95% CI 0.06 - 0.12, p<0.001) and SBP (B=0.02, 95% CI 0.01 - 0.04, p <0.005) and a negative correlation with treatment duration of with colchicine (B=-0.003, 95% CI -0.006 - 0.00, p<0.05). A linear inverse relationship was found between cf-PWV and the treatment duration even in the 3-18 age group. In the univariate analysis of covariance, the patient group cf-PWV values adjusted for age and SBP associated with frequency of attacks (for < 2 months vs. > 2 months, B= 0.48 95%CI 0.01 to 0.96, p<0.05). In conclusion, this doctoral thesis presented for the first time the long-term outcome of a large cohort of Greek patients, mainly pediatric, with the application of contemporary quantitative assessment tools and recorded the national profile of the disease. At the same time, patients were genotyped using the contemporary technique NGS in patients with non-confirmatory genotype. Finally, it assessed the cardiovascular risk in patients by measuring their arterial stiffness indices.The study examined and presented the following findings:- The application of conventional genotyping techniques PCR and NIRCA recorded the genetic profile of patients. The most common mutations were M694V (55.3%), M680I (29.8%), V726A (8.5%) and E148Q (7.4%).- The majority of patients presented mild to moderate disease severity.- Mutation M694V and homozygosity M694V/M694V were associated with higher disease severity. - FMF in Greece presents with mild course. The cornerstone for the satisfactory outcome of the disease is patient's compliance to treatment, which prevents the development of complications of the disease, with the main representative being renal amyloidosis.- The mutation R202Q is associated with the inflammatory phenotype of the disease and its presence contributes to its expression.- NGS is a method with increased sensitivity and specificity, useful in supporting clinical diagnosis.- The increased specificity of the NGS revealed the genetic heterogeneity of the patients, contributed to the clarification of the genetic profile of Greek patients with FMF and supported the management of the disease.- After the application of NGS the frequency of the mutations changed as follows: R202Q (61.3%), M694V (48.4%) and M680I (19.4%).- NGS detected rare mutations R761H, E148V, E167D, F479L, R408Q and P369S, some of which are not included in the mutation panel of all conventional methods.- Patients with FMF, in whom disease activity is not controlled, are at increased cardiovascular risk, as indicated by increased AIx75 values compared to healthy controls.- AIx75 was correlated with response to treatment and its duration, as well as with the genotype M694V/M680I.- Normal cf-PWV values in FMF patients may reflect patients' compliance to treatment.

Degree

thesis:*
Grantor dc:publisher
Aristotle University Of Thessaloniki (AUTH)
Year dc:date
2021

Author and committee

dc:creator, dc:contributor.*
Authors dc:creator
  • Sgouropoulou, Vasiliki
  • Σγουροπούλου, Βασιλική

Subjects

dc:subject × 16

Rights

dc:rights
Statement dc:rights
  • BY_NC_ND_4_0
Language dc:language
gre

Identifiers

dc:identifier.*
Identifier
10.12681/eadd/49523

Chain of custody

source
Harvested from
Greek National Archive of PhD Theses
Base URL
phdtheses.ekt.gr/eadd_oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
citation

Sgouropoulou, Vasiliki; Σγουροπούλου, Βασιλική. Γονοτύπηση με αλληλούχιση νέας γενιάς ασθενών με οικογενή μεσογειακό πυρετό και μακροχρόνια παρακολούθηση της πορείας της νόσου με σύγχρονες μεθόδους. Aristotle University Of Thessaloniki (AUTH), 2021. http://hdl.handle.net/10442/hedi/49523